Multidisciplinary focus on methotrexate in psoriatic disesase

Antonio Marchesoni, Massimo Ricci, Erica Moggio, Valeria Brazzelli, Giovanni Borroni

Research output: Contribution to journalArticle

Abstract

The aim of this focus is to establish the role of methotrexate (MTX) in the treatment of psoriatic disease (PD). Despite the lack of hard evidence, MTX can be regarded as the nonbiological drug of choice for the treatment of peripheral psoriatic arthritis, although its effect on psoriatic dactylitis, enthesitis, and spondylitis needs to be further studied by means of well conducted clinical trials.MTX is effective in improving the skin involvement of PD, and can be used in moderate to severe psoriasis before starting a biological agent. Although rheumatologists consider it relatively safe in PD, dermatologists are very concerned about its toxicity and so, until more definite data are available, precautions should be taken to prevent MTX-induced liver fibrosis and cirrhosis.

Original languageEnglish
Pages (from-to)56-58
Number of pages3
JournalJournal of Rheumatology
Volume36
Issue numberSUPPL. 83
DOIs
Publication statusPublished - Aug 2009

Fingerprint

Methotrexate
Liver Cirrhosis
Spondylitis
Psoriatic Arthritis
Biological Factors
Psoriasis
Clinical Trials
Skin
Therapeutics
Pharmaceutical Preparations

Keywords

  • Hepatotoxicity
  • Methotrexate
  • Psoriatic arthritis
  • Psoriatic disease

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)
  • Immunology and Allergy
  • Rheumatology

Cite this

Multidisciplinary focus on methotrexate in psoriatic disesase. / Marchesoni, Antonio; Ricci, Massimo; Moggio, Erica; Brazzelli, Valeria; Borroni, Giovanni.

In: Journal of Rheumatology, Vol. 36, No. SUPPL. 83, 08.2009, p. 56-58.

Research output: Contribution to journalArticle

Marchesoni, A, Ricci, M, Moggio, E, Brazzelli, V & Borroni, G 2009, 'Multidisciplinary focus on methotrexate in psoriatic disesase', Journal of Rheumatology, vol. 36, no. SUPPL. 83, pp. 56-58. https://doi.org/10.3899/jrheum.090226
Marchesoni, Antonio ; Ricci, Massimo ; Moggio, Erica ; Brazzelli, Valeria ; Borroni, Giovanni. / Multidisciplinary focus on methotrexate in psoriatic disesase. In: Journal of Rheumatology. 2009 ; Vol. 36, No. SUPPL. 83. pp. 56-58.
@article{4c5530a6fa8e43798bea538e4edc0742,
title = "Multidisciplinary focus on methotrexate in psoriatic disesase",
abstract = "The aim of this focus is to establish the role of methotrexate (MTX) in the treatment of psoriatic disease (PD). Despite the lack of hard evidence, MTX can be regarded as the nonbiological drug of choice for the treatment of peripheral psoriatic arthritis, although its effect on psoriatic dactylitis, enthesitis, and spondylitis needs to be further studied by means of well conducted clinical trials.MTX is effective in improving the skin involvement of PD, and can be used in moderate to severe psoriasis before starting a biological agent. Although rheumatologists consider it relatively safe in PD, dermatologists are very concerned about its toxicity and so, until more definite data are available, precautions should be taken to prevent MTX-induced liver fibrosis and cirrhosis.",
keywords = "Hepatotoxicity, Methotrexate, Psoriatic arthritis, Psoriatic disease",
author = "Antonio Marchesoni and Massimo Ricci and Erica Moggio and Valeria Brazzelli and Giovanni Borroni",
year = "2009",
month = "8",
doi = "10.3899/jrheum.090226",
language = "English",
volume = "36",
pages = "56--58",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "SUPPL. 83",

}

TY - JOUR

T1 - Multidisciplinary focus on methotrexate in psoriatic disesase

AU - Marchesoni, Antonio

AU - Ricci, Massimo

AU - Moggio, Erica

AU - Brazzelli, Valeria

AU - Borroni, Giovanni

PY - 2009/8

Y1 - 2009/8

N2 - The aim of this focus is to establish the role of methotrexate (MTX) in the treatment of psoriatic disease (PD). Despite the lack of hard evidence, MTX can be regarded as the nonbiological drug of choice for the treatment of peripheral psoriatic arthritis, although its effect on psoriatic dactylitis, enthesitis, and spondylitis needs to be further studied by means of well conducted clinical trials.MTX is effective in improving the skin involvement of PD, and can be used in moderate to severe psoriasis before starting a biological agent. Although rheumatologists consider it relatively safe in PD, dermatologists are very concerned about its toxicity and so, until more definite data are available, precautions should be taken to prevent MTX-induced liver fibrosis and cirrhosis.

AB - The aim of this focus is to establish the role of methotrexate (MTX) in the treatment of psoriatic disease (PD). Despite the lack of hard evidence, MTX can be regarded as the nonbiological drug of choice for the treatment of peripheral psoriatic arthritis, although its effect on psoriatic dactylitis, enthesitis, and spondylitis needs to be further studied by means of well conducted clinical trials.MTX is effective in improving the skin involvement of PD, and can be used in moderate to severe psoriasis before starting a biological agent. Although rheumatologists consider it relatively safe in PD, dermatologists are very concerned about its toxicity and so, until more definite data are available, precautions should be taken to prevent MTX-induced liver fibrosis and cirrhosis.

KW - Hepatotoxicity

KW - Methotrexate

KW - Psoriatic arthritis

KW - Psoriatic disease

UR - http://www.scopus.com/inward/record.url?scp=70349925315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349925315&partnerID=8YFLogxK

U2 - 10.3899/jrheum.090226

DO - 10.3899/jrheum.090226

M3 - Article

C2 - 19661543

AN - SCOPUS:70349925315

VL - 36

SP - 56

EP - 58

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - SUPPL. 83

ER -